QNRX / Quoin Pharmaceuticals, Ltd. - Depositary Receipt (Common Stock) - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Quoin Pharmaceuticals, Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary shares, no par value per share ("Ordinary Shares"), represented by American Depositary Shares ("

This Agreement

Exhibit 10.1 This Agreement is dated as of August 15, 2025 Parties: (1) Gordon Dunn of XXXXXXXXX (the Employee/you); and (2) Quoin Pharmaceuticals, Inc. a Delaware corporation with registered number SR 20181693856 whose principal place of business is at 42127 Pleasant Forest Court, Ashburn, VA 20148 (the Company/we/us, and, together with all other affiliated companies, including Quoin Pharmaceutic

Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan

Exhibit 4.4 Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of the Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan (as amended, this “Plan”) is to provide an incentive to Service Providers of Quoin Pharmaceuticals Ltd., an Israeli company (together with any successor corporation thereto, the “Company”), or any Affiliate

As filed with the Securities and Exchange Commission on August 27, 2025

As filed with the Securities and Exchange Commission on August 27, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss

As filed with the Securities and Exchange Commission on August 25, 2025

As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Quoin Pharmaceuticals, Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary shares, no par value per share ("Ordinary Shares"), represented by American Depositary Shares ("

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy August 18, 2025 ASHBURN, Va.

Form of Amendment to the Articles The Companies Law, 5759-1999 Quoin Pharmaceuticals Ltd., Company No. 52-003648-4 (the “Company”) Amendment to the Company's Articles of Association (the “Articles”) adopted at the Company's Annual General Meeting

Exhibit 3.1 Form of Amendment to the Articles The Companies Law, 5759-1999 Quoin Pharmaceuticals Ltd., Company No. 52-003648-4 (the “Company”) Amendment to the Company's Articles of Association (the “Articles”) adopted at the Company's Annual General Meeting If approved at the Annual Meeting, Section 4 of Part One of the Articles of Association will be mended to read as follows (additions are bold

Dated the 18th day of August 2025 Quoin Therapeutics (Ireland) Ltd SALLY LAWLOR SERVICE AGREEMENT

Exhibit 10.1 Dated the 18th day of August 2025 Quoin Therapeutics (Ireland) Ltd and SALLY LAWLOR SERVICE AGREEMENT CONTENTS 1 INTERPRETATION 3 2 APPOINTMENT 5 3 WARRANTY 6 4 DUTIES 6 5 EXCLUSIVITY OF SERVICE 6 6 PLACE OF WORK 7 7 NO OBLIGATION TO PROVIDE WORK 7 8 SALARY 7 9 EXPENSES 8 10 PENSION AND OTHER BENEFITS 8 11 ANNUAL LEAVE 8 12 INCAPACITY 9 13 USE OF INTELLECTUAL PROPERTY 10 14 DISCIPLINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update - Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome - I

Exhibit 99.1 Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update - Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome - Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study - Orphan Drug Designation Granted by European Medicines Agency

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study · Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. · Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at North

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulat

Exhibit 99.1 Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) - Quoin Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results May 13, 2025 Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline Growth Launch of NETHERT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

Material Modification to Rights of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

As filed with the Securities and Exchange Commission on March 28, 2025.

As filed with the Securities and Exchange Commission on March 28, 2025. Registration No. 333- 277016 Registration No. 333- 266476 Registration No. 333- 269543 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT NO. 333- 277016 UNDER THE SECURITIES ACT OF 1933 AND POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 REGISTR

Letter from Marcum LLP, dated March 20, 2025, addressed to the Securities and Exchange Commission

Exhibit 16.1 March 20, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Quoin Pharmaceuticals Ltd. under Item 4.01 of its Form 8-K dated March 20, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Quoin Pharmaceuticals Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd. (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K filed with the SEC on March 13, 2025).

Exhibit 3.1 PUBLIC COMPANY COMPANIES LAW, 5759–1999 A COMPANY LIMITED IN SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF QUOIN PHARMACEUTICALS LTD (PUBLIC CORPORATION 52-003648-4) Index Part One: Preamble 1 1. Name of the Company 1 2. Objectives of the Company 1 3. Liability of the shareholders 1 4. The capital 1 Part Two: General Provisions 1 5. Definitions and interpretation 1 6. Change o

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.15 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 10-K, Quoin Pharmaceuticals, Ltd., an Israeli company (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary

COO Compensation Program

Exhibit 10.46 Compensation Program for Denise Carter At the 2024 annual meeting of shareholders, the Company’s shareholders approved a compensation program for the Company’s Chief Operating Officer and a Member of the Board, Denise Carter. The program sets forth the following compensation limitations applicable to Ms. Carter which the Compensation Committee and the Board can utilize in setting Ms.

Non-Employee Directors’ Compensation Program, as amended

Exhibit 10.44 Non-Employee Directors’ Compensation Program, as amended Each non-employee director of Quoin Pharmaceuticals Ltd. is entitled to receive as compensation for their service (i) an annual cash retainer of $82,500, (ii) an annual option grant having a value of no less than $20,000 and no more than $60,000, with such value being determined annually at the discretion of the Compensation Co

Quoin Pharmaceuticals Ltd. Insider Trading Policy

Exhibit 19.1 Quoin Pharmaceuticals Ltd. Insider Trading Policy This Insider Trading Policy (“Policy”) provides the standards of Quoin Pharmaceuticals Ltd. (“Quoin” or the “Company”) with respect to transactions in securities of the Company and the handling of confidential information about Quoin and the companies with which Quoin does business. The federal securities laws prohibit insider trading.

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) – Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

CEO Compensation Program

Exhibit 10.45 Compensation Program for Dr. Michael Myers At the 2024 annual meeting of shareholders, the Company’s shareholders approved a compensation program for the Company’s Chief Executive Officer and Chairman of the Board, Dr. Michael Myers. The program sets forth the following compensation limitations applicable to Dr. Myers which the Compensation Committee and the Board can utilize in sett

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss

Annex A

Exhibit 99.1 Annex A The Reporting Person currently has the following outstanding options pursuant to the Issuer’s equity plans: Date of option grant Number of shares Exercise Price Per Share Vesting Schedule Expiration Date Portion Vested at 12/23/2024 4/12/2022 7,143 $210 Vests in four equal annual installments beginning on April 12, 2023. 04/12/2032 3,572 10/26/2023 80,965 $5.75 Vests in four a

Annex A

Exhibit 99.1 Annex A The Reporting Person currently has the following outstanding options pursuant to the Issuer’s equity plans: Date of option grant Number of shares Exercise Price Per Share Vesting Schedule Expiration Date Portion Vested at 12/23/2024 4/12/2022 7,143 $210 Vests in four equal annual installments beginning on April 12, 2023. 04/12/2032 3,572 10/26/2023 80,966 $5.75 Vests in four a

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi

Form of Series F Warrant

Exhibit 4.2   FORM OF SERIES F WARRANT TO PURCHASE ORDINARY SHARES   REPRESENTED BY AMERICAN DEPOSITARY SHARES   Quoin Pharmaceuticals Ltd.   Warrant ADSs: Initial Exercise Date: December 23, 2024   THIS SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms

Form of Series G Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on December 26, 2024).

Exhibit 4.3 FORM OF SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: December 23, 2024 THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subje

Placement Agency Agreement dated December 20, 2024 (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the SEC on December 26, 2024).

Exhibit 1.1 December 20, 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the "Agreement") between Maxim Group LLC, as the lead placement agent ("Maxim") (Maxim is also referred to herein as the "Placement Agent"), and Quoin Pharmaceuticals Ltd., a company or

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Exhibit 99.1 Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares rep

Form of Amendment to Warrants to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed with the SEC on December 26, 2024).

Exhibit 4.4 FORM OF AMENDMENT TO WarrantS to purchase ordinary shares represented by american depositary shares This AMENDMENT TO WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of December 20, 2024, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [·] (the “Holde

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on December 26, 2024).

Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 20, 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS,

Form of Pre-Funded Warrant issued in the December 2024 Offering (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on December 26, 2024).

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: December 23, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and s

3,137,778 Ordinary Shares Represented by American Depositary Shares 11,973,332 Pre-Funded Warrants to Purchase 11,973,332 Ordinary Shares Represented by American Depositary Shares 15,111,110 Series F Warrants to Purchase Up to 15,111,110 Ordinary Sha

Filed pursuant to Rule 424(b)(4) Registration No. 333-283734 3,137,778 Ordinary Shares Represented by American Depositary Shares 11,973,332 Pre-Funded Warrants to Purchase 11,973,332 Ordinary Shares Represented by American Depositary Shares 15,111,110 Series F Warrants to Purchase Up to 15,111,110 Ordinary Shares Represented by American Depositary Shares 15,111,110 Series G Warrants to Purchase Up

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on December 18, 2024

As filed with the Securities and Exchange Commission on December 18, 2024 Registration No.

42127 Pleasant Forest Court Ashburn, VA 20148-7349

42127 Pleasant Forest Court Ashburn, VA 20148-7349 December 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Form of Series G Warrant.

Exhibit 4.12 SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: , 2024 THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitati

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) QUOIN PHARMACEUTICALS LTD.

10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in

Form of Securities Purchase Agreement.

Exhibit 10.42 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the te

Form of Pre-Funded Warrant.

Exhibit 4.10 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limi

Form of Series F Warrant.

Exhibit 4.11   SERIES F WARRANT TO PURCHASE ORDINARY SHARES   REPRESENTED BY AMERICAN DEPOSITARY SHARES   Quoin Pharmaceuticals Ltd.   Warrant ADSs: Initial Exercise Date: , 2024   THIS SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to th

As filed with the Securities and Exchange Commission on December 11, 2024

As filed with the Securities and Exchange Commission on December 11, 2024 Registration No.

Form of Placement Agency Agreement.

Exhibit 1.1 [ ], 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the "Agreement") between Maxim Group LLC, as the lead placement agent ("Maxim") (Maxim is also referred to herein as the "Placement Agent"), and Quoin Pharmaceuticals Ltd., a company organized

Amendments to Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on December 5, 2024.

Exhibit 3.1 Form of Amendment to the Articles The Companies Law, 5759-1999 Quoin Pharmaceuticals Ltd., Company No. 52-003648-4 (the “Company”) Amendment to the Company's Articles of Association (the “Articles”) adopted at the Company's Annual General Meeting Section 19 of the Articles of Association is amended as follows (additions in underline and deletions in strikethrough): 19. Special General

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

QNRX / Quoin Pharmaceuticals, Ltd. - Depositary Receipt (Common Stock) / Lind Global Fund II LP Passive Investment

SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Quoin Pharmaceuticals Ltd. (Name of Issuer) American Depositary Shares (Title of Class of Securities) 74907L300 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d

JOINT FILING AGREEMENT

EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the American Depositary Shares of Quoin Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insi

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation)

10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants

424B3 1 tm2427874d2424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and suppl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

Other Events, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (C

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherto

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A O

10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ¨ Definiti

As filed with the Securities and Exchange Commission on March 29, 2024.

Table of Contents As filed with the Securities and Exchange Commission on March 29, 2024.

Clawback Policy

Exhibit 97.1 QUOIN PHARMACEUTICALS LTD. COMPENSATION RECOVERY POLICY 1. Purpose. The purpose of this compensation recovery policy (the “Policy”) of Quoin Pharmaceuticals Ltd. (the “Company”) is to enable the Company to recover reasonably promptly the amount of any Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is designe

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.19 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 10-K, Quoin Pharmaceuticals, Ltd., an Israeli company (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with p

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to four

Securities Purchase Agreement dated March 4, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter

Form of Pre-Funded Warrant issued in the 2024 Offering (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).

Exhibit 4.1 PRE-FUNDED warrant To purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the

Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important de

Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development re

811,250 Ordinary Shares Represented by 811,250 American Depositary Shares 3,251,250 Pre-Funded Warrants to Purchase 3,251,250 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series D Warrants to Purchase 4,062,500 Ordinary Shares

Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT (to Prospectus dated March 4, 2024) 811,250 Ordinary Shares Represented by 811,250 American Depositary Shares 3,251,250 Pre-Funded Warrants to Purchase 3,251,250 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series D Warrants to Purchase 4,062,500 Ordinary Shares Represented by American Deposit

Form of Series E Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).

Exhibit 4.3 Series E - WARRANT to purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 Original Issuance Date: [●], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the t

Placement Agency Agreement dated March 4, 2024 (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).

Exhibit 1.1 [ ], 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the lead placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

Exhibit 99.2 Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,06

863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef

Form of Amendment to Warrants to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).

Exhibit 4.4 AMENDMENT TO WarrantS to purchase ordinary shares represented by american depositary shares This AMENDMENT TO WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of March [●], 2024, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [●] (the “Holder”). WHERE

Form of Series D Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).

Exhibit 4.2 Series D - WARRANT to purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 Original Issuance Date: [●], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the t

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi

811,250 Ordinary Shares Represented by 811,250 American Depositary Shares 3,251,250 Pre-Funded Warrants to Purchase 3,251,250 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series D Warrants to Purchase 4,062,500 Ordinary Shares

Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-277016 811,250 Ordinary Shares Represented by 811,250 American Depositary Shares 3,251,250 Pre-Funded Warrants to Purchase 3,251,250 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series D Warrants to Purchase 4,062,500 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series E Warrants t

Up to 2,089,552 Ordinary Shares Represented by American Depositary Shares Up to 2,089,552 Pre-Funded Warrants to Purchase Up to 2,089,552 Ordinary Shares Represented by American Depositary Shares Up to 2,089,552 Series D Warrants to Purchase Up to 2,

Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 The information in this preliminary prospectus is not complete and may be changed. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Preliminary Prospectus Subject to Completion, Dated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

42127 Pleasant Forest Court Ashburn, VA 20148-7349

42127 Pleasant Forest Court Ashburn, VA 20148-7349 February 14, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

February 14, 2024

February 14, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Re: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 File No. 333-277016 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (t

Form of Securities Purchase Agreement.

Exhibit 10.36 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the te

As filed with the Securities and Exchange Commission on February 13, 2024

Table of Contents As filed with the Securities and Exchange Commission on February 13, 2024 Registration No.

US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / Lind Global Fund II LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Quoin Pharmaceuticals Ltd. (Name of Issuer) American Depositary Shares (Title of Class of Securities) 74907L201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the American Depositary Shares of Quoin Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. February 13, 2024 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC its Gene

Form of Placement Agency Agreement.

Exhibit 1.1 [ ], 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the lead placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ¨ Definitive Proxy Stat

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) QUOIN PHARMACEUTICALS LTD.

Form of Pre-Funded Warrant

Exhibit 4.17 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to th

Form of Series D Common Warrant

Exhibit 4.18 SERIES D - WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2024 Original Issuance Date: [•], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the

As filed with the Securities and Exchange Commission on February 12, 2024

Table of Contents As filed with the Securities and Exchange Commission on February 12, 2024 Registration No.

Form of Series E Common Warrant

Exhibit 4.19 SERIES E - WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2024 Original Issuance Date: [•], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the

863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

Purchase Agreement, dated January 25, 2024, by and between Quoin Pharmaceuticals Ltd. and Alumni Capital LP (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on January 30, 2024).

Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (this “Agreement”), dated as of January 25, 2024 (the “Execution Date”), by and between QUOIN PHARMACEUTICALS LTD., an Israeli company (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor

863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower

Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., December 13, 20

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits w

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment. No

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef

51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P

Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis

51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A NFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A NFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi

License and Distribution Agreement, by and between Quoin Pharmaceuticals Inc. and Farma Mondo (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on September 13, 2023)

Exhibit 10.1 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT (version 28 July 2023) This License and Distribution Agreement (this “Agreement”), dated as of September 1, 2023 (“Eff

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was assesse

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was assessed to be fully clear by Investigator at QRX003 treatment areas Subject also demonstrated key improvements across all other clinical endpoi

51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss

51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD.

51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants

424B3 1 tm2311915d2424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recr

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome Following succes

51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of the Common Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of the Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of the Common Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333- 266476 Registration No. 333- 269543 Prospectus 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of the Common Warrants This prospectus relates to the issuance by Quoin Pharmaceuticals Ltd. of 51,800,000,000 ordinary shares represented by 10,360,000 American Depositary Shares, or “ADSs,”

Filing Fee Table

Exhibit 107 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD.

As filed with the Securities and Exchange Commission on March 15, 2023.

Table of Contents As filed with the Securities and Exchange Commission on March 15, 2023.

Code of Ethics and Business Conduct (incorporated by reference to Exhibit 14.1 to Form 10-K filed with the SEC on March 15, 2023)

Exhibit 14.1 QUOIN PHARMACEUTICALS LTD. CODE OF ETHICS AND BUSINESS CONDUCT I. INTRODUCTION This Code of Ethics and Business Conduct (this “Code”) contains general guidelines for conducting the business of Quoin Pharmaceuticals Ltd. and its subsidiaries (collectively, the “Company” or “Quoin”) and applies to all of the Company’s directors, officers and employees. We refer to all officers and other

As filed with the Securities and Exchange Commission on March 15, 2023

As filed with the Securities and Exchange Commission on March 15, 2023 Registration No.

Description of Ordinary Shares.

Exhibit 99.1 The following description of our securities registered pursuant to the Securities Exchange Act of 1934 is a summary of the material terms of our articles of association, Israeli corporate law and such securities. This description contains all material information concerning such securities but does not purport to be complete. DESCRIPTION OF ORDINARY SHARES Ordinary Shares As of March

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter And Full Year 2022 Financial Results

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter And Full Year 2022 Financial Results · Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton Syndrome · Quoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy · C

US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / Lind Global Fund II LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Quoin Pharmaceuticals Ltd. (Name of Issuer) American Depository Shares (Title of Class of Securities) 74907L201 (CUSIP Number) February 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

JOINT FILING AGREEMENT

EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the American Depository Shares of Quoin Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13

Regulation FD Disclosure, Financial Statements and Exhibits, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 n/a (State or other jurisdiction of incorporation) (Commission F

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).

Exhibit 4.1 PRE-FUNDED warrant To purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: February 24, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subjec

24,750,000,000 Ordinary Shares Represented by 4,950,000 American Depositary Shares Pre-Funded Warrants to Purchase 10,250,000,000 Ordinary Shares Represented by 2,050,000 American Depositary Shares Common Warrants to Purchase 35,000,000,000 Ordinary

Filed pursuant to Rule 424(b)(3) SEC File No. 333-269543 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated February 22, 2023) 24,750,000,000 Ordinary Shares Represented by 4,950,000 American Depositary Shares Pre-Funded Warrants to Purchase 10,250,000,000 Ordinary Shares Represented by 2,050,000 American Depositary Shares Common Warrants to Purchase 35,000,000,000 Ordinary Shares Represented by 7,0

Placement Agency Agreement by and between A.G.P. / Alliance Global Partners and Quoin Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on February 28, 2023

Exhibit 10.2 February 22, 2023 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Age

Form of Securities Purchase Agreement, dated February 22, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 22, 2023, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject

Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).

Exhibit 4.2 WARRANT to purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: February 24, 2023 Original Issuance Date: February 24, 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time

Form of Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).

Exhibit 4.3 AMENDMENT NO. 1 TO Warrant to purchase ordinary shares represented by american depositary shares This AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of February 24, 2023, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [●] (the “Hol

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Exhibit 99.1 Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering ASHBURN, Va., February 22, 2023 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 24,750,000,000 ordinary sh

24,750,000,000 Ordinary Shares Represented by 4,950,000 American Depositary Shares Pre-Funded Warrants to Purchase 10,250,000,000 Ordinary Shares Represented by 2,050,000 American Depositary Shares Common Warrants to Purchase 35,000,000,000 Ordinary

Table of Contents Prospectus Filed Pursuant to Rule 424(b)(4) Registration No. 333-269543 24,750,000,000 Ordinary Shares Represented by 4,950,000 American Depositary Shares Pre-Funded Warrants to Purchase 10,250,000,000 Ordinary Shares Represented by 2,050,000 American Depositary Shares Common Warrants to Purchase 35,000,000,000 Ordinary Shares Represented by 7,000,000 American Depositary Shares 1

US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 74907L201 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Quoin Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 74907L201 (CUSIP Number) Dece

US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / GOLDMAN SACHS GROUP INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* QUOIN PHARMACEUTICALS, LTD. - (Name of Issuer) American Depositary Shares, each representing 5,000 Ordinary Shares, no par value per share - (Title of Class of Securities) 74907L201 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filin

February 9, 2023

CORRESP 1 filename1.htm February 9, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 File No. 333-269543 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the

As filed with the Securities and Exchange Commission on February 8, 2023.

Table of Contents As filed with the Securities and Exchange Commission on February 8, 2023.

Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349

Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 February 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 Registration No. 333-269543 Ladies and Gentlemen: Quoin Pharmaceuticals Ltd. (the “Company”) hereby reques

Registration No. 333 269543

Exhibit 107 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD.

1

February 8, 2023 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services U.

Form of Pre-Funded Warrant.

Exhibit 4.15 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to th

As filed with the Securities and Exchange Commission on February 2, 2023.

Table of Contents As filed with the Securities and Exchange Commission on February 2, 2023.

Form of Common Warrant.

Exhibit 4.16 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2023 Original Issuance Date: [•], 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and s

Form of Securities Purchase Agreement.

Exhibit 4.14 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2023, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the

Form of Placement Agency Agreement.

Exhibit 1.1 [•], 2023 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and

Filing Fee Table

Exhibit 107 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (No. 2) Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (No. 2) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes, which are included elsewhere in this Form 6-K, and our audited consolidated financial statements a

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

September 30,

Table of Contents Exhibit 99.1 QUOIN PHARMACEUTICALS LTD. Condensed Consolidated Financial Statements as of September 30, 2022 and December 31, 2021 and for the three and nine months ended September 30, 2022 and 2021 (unaudited) Table of Contents QUOIN PHARMACEUTICALS LTD. Contents Page Condensed Consolidated Financial Statements (Unaudited) Consolidated Balance Sheets as of September 30, 2022 and

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

424B3 1 tm2229920d3424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (a

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (No. 1) Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (No. 1) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd

Consent of Friedman LLP

EX-16.1 2 tm2229920d1ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM November 7, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Quoin Pharmaceuticals, LTD Commission File Number 001-37846 Commissioners: We have read the statements made by Quoin Pharmaceuticals, LTD of its Form 6-K dated November 7, 2022. We agree wi

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

424B3 1 tm2229097d3424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 (No. 1) Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 (No. 1) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.2 PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of Quoin Pharmaceuticals Ltd. (the “Company”) hereby appoints Gordon Dunn and Briana Hayes, or either of them, as agents and proxies of the undersigned, with full power of substitution to each of them, to appear, and to vote on behalf of the undersigned all ordinary shares of the Company whic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (No. 1) Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (No. 1) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blv

Voting Instruction Form

Exhibit 99.3

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 27, 2022

Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 27, 2022 Notice is hereby given that an Annual General Meeting (the ?Annual Meeting?) of Shareholders of Quoin Pharmaceuticals Ltd. (the ?Company?) will be held at The Logan, One Logan Square, Philadelphia, PA 19103, at 12:00 pm, US Eastern Time, on October 27, 2022. The Annual Meeting is being called for the follo

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.2 3 qnrx-20220630xex99d2.htm EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes, which are included elsewhere in this Form 6-K, and our

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

June 30,

Table of Contents Exhibit 99.1 ? ? ? ? ? ? ? ? ? QUOIN PHARMACEUTICALS LTD. ? Condensed Consolidated Financial Statements as of June 30, 2022 and December 31, 2021 and for the three and six months ended June 30, 2022 and 2021 (unaudited) ? ? ? ? 1 Table of Contents QUOIN PHARMACEUTICALS LTD. Contents ? ? ? ? ? Page ? ? Condensed Financial Statements (Unaudited) ? ? Consolidated Balance Sheets as o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 (No. 2) Commission File Number

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 (No. 2) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Bl

QNRX / Quoin Pharmaceuticals Ltd - ADR / CVI Investments, Inc. - SC 13G Passive Investment

CUSIP No: ?????74907L201 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* Quoin Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 74907L201 (CUSIP Number)

As filed with the U.S. Securities and Exchange Commission on August 11, 2022.

As filed with the U.S. Securities and Exchange Commission on August 11, 2022. Registration No. 333-264305 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUOIN PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 99.4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Quoin Pharmaceuticals Ltd. Opinion on the Financial Statements We have audited the accompanying balance sheets of Quoin Pharmaceuticals Ltd. (the ?Company?) as of December 31, 2021 and 2020, the related statements of operations, and shareholders? equity (deficit), and cash flows f

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.5 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion together with the consolidated financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements regarding our expectations regarding our future performance, liquidity and capital resources, as well a

Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

Exhibit 99.2 Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering ASHBURN, Va., August 9, 2022 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the ?Company? or ?Quoin?), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the closing of its previously announced public offering of 11,050,000,000 ordinary shares re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 (No. 1) Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 (No. 1) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant?s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd T

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0

6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares

Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time

March 31,

Exhibit 99.3 ? QUOIN PHARMACEUTICALS LTD. Consolidated Balance Sheets ? ? ? ? ? ? ? ? ? March 31, ? ? ? ? 2022 ? December 31, ? ? (unaudited) ? 2021 ASSETS ? ? Current assets: ? ? Cash ? $ 5,189,215 ? $ 7,482,773 Prepaid expenses ? 809,466 ? 1,015,474 Total current assets ? 5,998,681 ? 8,498,247 ? ? ? ? ? ? ? Intangible assets, net ? 782,594 ? 808,604 Other assets ? 50,000 ? 50,000 Total assets ?

Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

Exhibit 99.1 Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering ASHBURN, Va., August 5, 2022 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the ?Company? or ?Quoin?), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 11,050,000,000 ordin

11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary S

Table of Contents ? ? Filed Pursuant to Rule 424(b)(4) Registration No. 333-266476 PROSPECTUS 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,000 American Depositary Share

As filed with the U.S. Securities and Exchange Commission on August 5, 2022.

As filed with the U.S. Securities and Exchange Commission on August 5, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUOIN PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into English) State of Israel 283

Filing Fee Table

Exhibit 107 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD.

Form of Securities Purchase Agreement, dated August 5, 2022 (incorporated by reference to Exhibit 4.11 of the Registration Statement on Form F-1/A filed with the SEC on August 4, 2022).

Exhibit 4.11 ? SECURITIES PURCHASE AGREEMENT ? This Securities Purchase Agreement (this ?Agreement?) is dated as of August [?], 2022, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). ? WHEREAS, su

As filed with the U.S. Securities and Exchange Commission on August 4, 2022.

Table of Contents ? ? As filed with the U.S. Securities and Exchange Commission on August 4, 2022. Registration No. 333-266476 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUOIN PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Tra

Registration No. 333 266476

Exhibit 107 FORM F-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD.

Quoin Pharmaceuticals Ltd. Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101

CORRESP 1 filename1.htm Quoin Pharmaceuticals Ltd. Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 August 4, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook RE: Quoin Pharmaceuticals Ltd. Registration Statement on Form F-1 Registration No. 333-266476

Form of Placement Agency Agreement.

Exhibit 1.1 August [·], 2022 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent

August 4, 2022

August 4, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Quoin Pharmaceuticals Ltd. Registration Statement on Form F-1 File No. 333-266476 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the ?Act?), A.G.P./ALLIANCE GL

Form of Placement Agency Agreement.

Exhibit 1.1 August [●], 2022 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent

Form of Common Warrant (incorporated by reference to Exhibit 4.13 of the Registration Statement on Form F-1 filed with the SEC on August 3, 2022).

Exhibit 4.13 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: August [•], 2022 Original Issuance Date: August [•], 2022 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.12 of the Registration Statement on Form F-1 filed with the SEC on August 3, 2022).

Exhibit 4.12 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: August [●], 2022 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t

As filed with the U.S. Securities and Exchange Commission on August 2, 2022.

Table of Contents As filed with the U.S. Securities and Exchange Commission on August 2, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUOIN PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) S

Form of Non-Qualified Stock Option Award Agreement for directors (incorporated by reference to Exhibit 10.34 to Form F-1 filed with the SEC on August 3, 2022)

Exhibit 10.34 FORM QUOIN PHARMACEUTICALS LTD. NON-QUALIFIED OPTION AWARD This is a Non-Qualified Stock Option Award Agreement (a/k/a “Grant Notification Letter”) dated April 12, 2022 (together with all schedules hereto, this “Agreement”) is entered into by and between Quoin Pharmaceuticals Ltd. (the “Company”) and (the “Grantee”). 1.Definitions. The following terms have the meanings ascribed to th

Form of Non-Qualified Stock Option Award Agreement for officers (incorporated by reference to Exhibit 10.35 to Form F-1 filed with the SEC on August 3, 2022)

Exhibit 10.35 FORM QUOIN PHARMACEUTICALS LTD. NON-QUALIFIED OPTION AWARD This is a Non-Qualified Stock Option Award Agreement (a/k/a “Grant Notification Letter”) dated April 12, 2022 (together with all schedules hereto, this “Agreement”) is entered into by and between Quoin Pharmaceuticals Ltd. (the “Company”) and (the “Grantee”). 1. Definitions. The following terms have the meanings ascribed to t

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD.

Form of Securities Purchase Agreement.

Exhibit 4.11 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August [●], 2022, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject

Form of Placement Agent's Warrant

Exhibit 4.14 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: August [•], 2022 Original Issuance Date: August [•], 2022 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the

Agreement, dated July 14, 2022, by and among Quoin Pharmaceuticals, Inc., Quoin Pharmaceuticals Ltd. and Altium Growth Fund, LP (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on July 15, 2022).

Exhibit 10.1 Execution Version AGREEMENT THIS AGREEMENT (this ?Agreement?), dated as of July 14, 2022 (the ?Effective Date?), is entered into by and among Quoin Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 42127 Pleasant Forest Ct, Ashburn, VA 20148 (?Quoin?), Quoin Pharmaceuticals Ltd. (formerly known as Cellect Biotechnology Ltd.), an Israeli company, with headquar

6,435,548,000 Ordinary Shares Represented by 16,088,870 American Depositary Shares

Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 16,088,870 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time